On January 18, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the National Reimbursable Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022) ("National Reimbursement Drug List"). Hansoh Pharma's two innovative drugs were successfully included in the National Reimbursable Drug List, and two other innovative drugs were successfully renewed. Up to now, Hansoh Pharma's all six innovative drugs available in the market have been included in the National Reimbursable Drug List.
Ameile (aumolertinib mesylate tablets) is a targeted drug for EFGR mutated non-small cell lung cancer (NSCLC) independently developed by Hansoh Pharma, and has been newly included in the National Reimbursable Drug List for first-line therapeutic indications. With the inclusion of both indications of Ameile in the National Reimbursable Drug List, Chinese NSCLC patients will have greater access to the drug.
Xinyue (inebilizumab injection) was introduced by Hansoh Pharma and has been successfully included in the National Reimbursable Drug List. It is a humanized anti-CD19 mAb for the treatment of adult patients with AQP4 antibody positive neuromyelitis optica spectrum disorders (NMOSD). NMOSD is a rare neurological autoimmune disease with high recurrence and high disability, mainly involving the optic nerve and spinal cord. China is currently a country with a large number of NMOSD patients in the world, and the disease is highly prevalent in the young and middle-aged female population. The new addition of inebilizumab injection in the National Reimbursable Drug List this time will help NMOSD patients reduce the number of relapses and hospitalizations, lower medical and nursing costs, minimize disability and return to normal social life.
In the National Reimbursable Drug List, Hansoh Pharma's innovative drugs Hansoh Xinfu (flumatinib mesylate tablets) and Fulaimei (PEG-loxenatide for injection) were also successfully renewed.
Hansoh Xinfu is an innovative drug for chronic myeloid leukemia (CML) developed independently in China, which was included in the National Reimbursable Drug List for the first time in December 2020, providing doctors in the field of hematological oncology with a new tool for the treatment of CML and effectively reducing the burden of medication for patients.
Fulaimei is a long-acting GLP-1 hypoglycemic drug originally developed in China, used to improve blood glucose control in patients with type 2 diabetes. It was included in the National Reimbursable Drug List at the end of December 2020.
The successful inclusion or renewal of Hansoh Pharma's four new innovative drugs this time, together with the previous inclusion of Hengmu (tenofovir amibufenamide tablets) and Mailingda (morinidazole sodium chloride injection), means that up to now, all six innovative drugs of Hansoh Pharma have been included in the National Reimbursable Drug List. This will help improve the accessibility and affordability of innovative drugs in China and benefit a wider range of Chinese patients, and also demonstrates the country's protection of the value of innovative drugs and its strong support for innovative drug companies.
